Japan has ended full reimbursement coverage for COVID-19 treatments, including antivirals, under its national health insurance (NHI) scheme and is planning to gradually increase patient co-payments to usual levels over the next six months.
From 1 October to 31 March 2024, individual patients will basically be charged up to a maximum of JPY9,000 ($60) for drugs used in each round of treatment